Hims and Hers Health Inc vs Micron Technology, Inc. — how do they compare? Hims and Hers Health Inc trades at $30.82 (market cap $6.55B), while Micron Technology, Inc. trades at $1,028.5 (market cap $1.17T). The key difference: Micron Technology, Inc. is far larger — about 178.6× Hims and Hers Health Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Micron Technology, Inc. for 48 Days on average.
| HIMS | MU | |
|---|---|---|
Market Cap | $6.55B | $1.17T |
Volume | 14,842,814 | 29,425,906 |
Sector | Health | Technology |
52-Week High | $62.76 | $1.21K |
52-Week Low | $14.52 | $181.60 |
Typical Hold Time | 21 Days | 48 Days |
Enterprise Value | $7.25B | $1.13T |
Dividend Yield | — | 0.06% |
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $30.12, up 1.96% on the day, amid a bearish technical outlook and mixed fundamentals. The stock faces headwinds from a securities class action lawsuit related to an FTC complaint, with multiple law firms alerting investors ahead of a November 2, 2026 deadline. Financially, revenue grew to $2.35 billion in 2025, but net income turned negative in 2026, with a net loss of $142 million and a profit margin of -5.51%. Analyst consensus is a 'Hold' with a $32.17 price target, indicating limited upside from current levels.
The outlook for HIMS is cautious due to legal overhangs and profitability challenges. Investment opportunities hinge on resolving regulatory issues and returning to earnings growth, but risks include prolonged litigation, competitive pressures, and execution missteps. The stock's high valuation multiples, such as a P/E of 57.14, add vulnerability if growth disappoints.
Micron Technology (MU) trades at $1,029, down 5.42% over the past session, despite strong fundamental performance. The stock shows bullish technical signals with robust earnings beats in recent quarters (Q2 2026 EPS of $33.42 vs. $31.77 expected) and exceptional profitability metrics, including a 63.8% net income margin. Recent news highlights multi-year growth driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030.
Outlook remains positive with analyst consensus strongly bullish (82.85% buy ratings) and a $1,590 price target, though risks include cyclical memory pricing and potential AI demand normalization. The company's strong cash flow generation ($17.53B operating cash flow in 2025) and expanding margins support continued upside potential for long-term investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →